Porton Advanced Solutions Ltd. (“Porton Advanced Solutions”) and Hangzhou Aisijia Biotech Co., Ltd. (“Aisijia Biotech”) announced a strategic collaboration centered on the new drug clinical trial (IND) application in China for an adult pancreatic progenitor cell therapy project for diabetes. Under the agreement, Porton Advanced Solutions will provide process development, GMP manufacturing and IND filing support, helping to accelerate the innovative therapy into the clinical stage.
Collaboration Milestone
| Item | Detail |
|---|---|
| Parties | Porton Advanced Solutions Ltd.; Hangzhou Aisijia Biotech Co., Ltd. |
| Agreement Type | Strategic collaboration |
| Announcement Date | 16 Oct 2026 |
| Project | Adult pancreatic progenitor cell therapy for diabetes |
| Core Objective | China new drug clinical trial (IND) application |
| Porton Advanced Solutions Scope | Process development; GMP manufacturing; IND filing support |
| Financial Terms | Not disclosed |
Project Profile – Autologous Adult Pancreatic Progenitor Cell Therapy
- Technology Route: An autologous transplantation technology using adult pancreatic progenitor cells – leveraging the patient’s own cells, an approach intended to minimize immune rejection relative to allogeneic cell therapies.
- Target Disease: The therapy is expected to be used for the treatment of diabetes, a chronic metabolic disease with a large and growing patient population in China (indication specifics and trial population not disclosed).
- Developer: Aisijia Biotech, which focuses on the R&D and translation of autologous adult stem cell therapy technologies.
- Development Stage: The collaboration targets the China IND application, marking the program’s push from preclinical development into the clinical stage (current development status details not disclosed).
Collaboration Scope – End‑to‑End CDMO Support
- Process Development: Porton Advanced Solutions will lead process development for the pancreatic progenitor cell therapy – a critical step in translating an autologous cell technology into a scalable, reproducible manufacturing process.
- GMP Manufacturing: The CDMO will provide GMP manufacturing of clinical‑grade cell therapy material to support the planned IND application.
- Regulatory Filing Support: IND filing support for the China new drug clinical trial application, pairing manufacturing deliverables with regulatory documentation.
- Platform Breadth: Porton Advanced Solutions has established CDMO service capabilities covering mainstream cell therapy technology routes, positioning it to serve the specialized requirements of progenitor cell programs.
Company Profiles
- Aisijia Biotech: A Hangzhou‑based biotech focused on the research, development and translation of autologous adult stem cell therapy technologies, with its adult pancreatic progenitor cell transplantation platform aimed at diabetes treatment.
- Porton Advanced Solutions: A cell and gene therapy CDMO whose service capabilities span mainstream cell therapy technology routes, offering integrated development, manufacturing and regulatory support to innovative therapy developers.
Market Impact & Outlook
- Regenerative Medicine Momentum: The partnership adds to China’s accelerating pipeline of stem cell–derived diabetes therapies, as regulators and industry converge on clear IND pathways for cell therapy products.
- CDMO Demand Signal: For Porton Advanced Solutions, the engagement demonstrates demand for integrated process‑to‑IND services among early‑stage cell therapy developers without in‑house GMP capacity.
- Autologous Platform Differentiation: Aisijia’s autologous approach differentiates its program from the predominantly allogeneic or stem cell–derived islet replacement strategies in the diabetes cell therapy field.
- Watch Items: Progress of the China IND application, subsequent clinical trial initiation and any expansion of the collaboration beyond the initial filing (timelines not disclosed).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic collaboration between Porton Advanced Solutions and Aisijia Biotech, including the China IND application, process development and GMP manufacturing activities, and the potential clinical advancement of the adult pancreatic progenitor cell therapy for diabetes. Actual results may differ materially due to risks including regulatory review outcomes, manufacturing and quality challenges, clinical trial results, and competitive dynamics. Successful IND filing does not guarantee eventual marketing approval of the therapy.-Fineline Info & Tech
